Hematological conditions and their treatments have an increased risk of cardiovascular events, and invasive interventions have a higher risk of periprocedural complications in this group of patients. The aim of this review was to evaluate the risk of invasive interventions in patients with hematologic disorders and to underline the role of noninvasive cardiovascular screening in patients with hematological disorders such as Hodgkin and non-Hodgkin lymphoma, anemia, hemophilia, thrombocythemia, polycythemia vera, and leukemia. Based on present knowledge in the field, our opinion is that the screening of patients with hematological diseases is very important to reduce the morbidity and mortality due to cardiovascular events. Noninvasive assessments are suitable for this purpose with a significantly lower risk compared to invasive interventions.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Benedek I Lazar E Keri-Sandor J et al. Acute Coronary Syndromes in Petients with Hematological Disorders. Journal of Cardiovascular Emergencies. 2016;2:159-168.
2. Kahn JM Keegan TH Tao L Abrahão R Bleyer A Viny AD. Racial disparities in the survival of American children adolescents and young adults with acute lymphoblastic leukemia acute myelogenous leukemia and Hodgkin lymphoma. Cancer. 2016;122:2723-2730.
3. Gottlieb I Lima JA. Screening High-Risk Patients With Computed Tomography Angiography. Circulation. 2008;117:1318-1332.
4. Doris M Newby DE. Coronary CT Angiography as a Diagnostic and Prognostic Tool: Perspectives from the SCOT-HEART Trial. Curr Cardiol Rep. 2016;18:18.
5. Kupeli S. Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors. World J Cardiol. 2014;6:555-561.
6. Kupeli S. Cardiovascular disease after Hodgkin’s lymphoma: a role for screening. Lancet Haematol. 2015;2:e461-e462.
7. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154:23-31.
8. Lipshultz SE Adams MJ Colan SD et al. Long-term cardiovascular toxicity in children adolescents and young adults who receive cancer therapy: pathophysiology course monitoring management prevention and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128:1927-1995.
9. Daniëls LA Krol AD de Graaf MA et al. Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance. Ann Oncol. 2014;25:1198-1203.
10. Rademaker J Schöder H Ariaratnam NS et al. Coronary artery disease after radiation therapy for Hodgkin’s lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR Am J Roentgenol. 2008;191:32-37.
11. Küpeli S Hazirolan T Varan A et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol. 2010;28:1025-1030.
12. Hoffmann MH Shi H Schmitz BL et al. Noninvasive coronary angiography with multislice computed tomography. JAMA. 2005;293:2471-2478.
13. Groarke JD Nguyen PL Nohria A Ferrari R Cheng S Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for noninvasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35:612-623.
14. Girinsky T M’Kacher R Lessard N et al. Prospective Coronary Heart Disease Screening in Asymptomatic Hodgkin Lymphoma Patients Using Coronary Computed Tomography Angiography: Results and Risk Factor Analysis. Int J Radiat Oncol Biol Phys. 2014;89:59-66.
15. Raposeiras Roubín S Abu-Assi E Iglesias Álvarez D González Ferreiro R García Acuña JM González Juanatey JR. Therapeutic Strategy in Patients With Severe Anemia Admitted for Non-ST-segment Elevation Acute Coronary Syndrome and Prognostic Impact. Rev Esp Cardiol (Engl Ed). 2014;67:1058-1059.
16. Rathod KS Jones DA Rathod VS et al. Prognostic impact of anaemia on patients with ST-elevation. Coron Artery Dis. 2014;25:52-59.
17. Tuinenburg A Mauser-Bunschoten EP Verhaar MC Biesma DH Schutgens RE. Cardiovascular disease in patients with hemophilia: Cardiovascular disease in patients with hemophilia. J Thromb Haemost. 2009;7:247-254.
18. Darby SC Kan SW Spooner RJ et al. Mortality rates life expectancy and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815-825.
19. Srámek A Reiber JH Gerrits WB Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation. 2001;104:762-767.
20. Ferrario C Renders F Cairoli A Vuffray A Spertini O Angelillo-Scherrer A. Management of an acute coronary syndrome in a patient with severe haemophilia A. Haemophilia. 2007;13:763-765.
21. Girolami A Ruzzon E Fabris F Varvarikis C Sartori R Girolami B. Myocardial Infarction and Other Arterial Occlusions in Hemophilia A Patients. Acta Haematol. 2006;116:120-125.
22. Spiel AO Gilbert JC Jilma B. Von Willebrand Factor in Cardiovascular Disease. Focus on Acute Coronary Syndromes. Circulation. 2008;117:1449-1459.
23. Schutgens RE Tuinenburg A Roosendaal G Guyomi SH Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia. 2009;15:952-958.
24. Mannucci PM Schutgens RE Santagostino E Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with haemophilia. Blood. 2009;114:5256-5263.
25. Lim MY Pruthi RK. Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: A single center experience and review of the literature. Thromb Res. 2012;130:316-322.
26. Zwiers M Lefrandt JD Mulder DJ et al. Coronary artery calcification score and carotid intima–media thickness in patients with hemophilia. J Thromb Haemost. 2012;10:23-9.
27. Natelson EA. Extreme Thrombocytosis and Cardiovascular Surgery: Risks and Management. Tex Heart J. 2012;39:792-798.
28. Das SS Bose S Chatterjee S Parida AK Pradhan SK. Thrombocytapheresis: managing essential thrombocythemia in a surgical patient. Ann Thorac Surg. 2011;92:e5-e6.
29. Wolberg AS Aleman MM Leiderman K Machlus KR. Procoagulant Activity in Hemostasis and Thrombosis: Virchow’s Triad Revisited. Anesth Analg. 2012;114:275-285.
30. Wagener JF Rao SV. Radial Artery Occlusion After Transradial Approach to Cardiac Catheterization. Curr Atheroscler Rep. 2015;17:489.
31. Tilling L Hunt J Donald A Clapp B Chowienczyk P. Arterial Injury and Endothelial Repair: Rapid Recovery of Function after Mechanical Injury in Healthy Volunteers. Cardiology Research and Practice. 2014;2014:7.
32. Ruggeri M Rodeghiero F Tosetto A et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008;111:666-671.
33. Vidwan P Lee S Rossi JS Stouffer GA. Relation of Platelet Count to Bleeding and Vascular Complications in Patients Undergoing Coronary Angiography. Am J Cardiol. 2010;105:1219-1222.
34. Ulrich B Kreienbühl G. Complication After Artery Catheterization: Digital Gangrene in a Patient with Myeloproliferative Disease with Thrombocytosis. Anesth Analg. 2000;91:767-768.
35. Madjid M Awan I Willerson JT Casscells SW. Leukocyte count and coronary heart disease. Implications for risk assessment. J Am Coll Cardiol. 2004;44:1945-1956.
36. Naruko T Ueda M Haze K van der Wal AC et al. Neutrophil Infiltration of Culprit Lesions in Acute Coronary Syndromes. Circulation. 2002;106:2894-2900.
37. Kantarjian HG. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib or with the T315I mutation: Longer-term follow up of the PACE trial. J Clin Oncol. 32:5s 2014 (suppl; abstr 7081)
38. Moslehi JJ Deininger M. Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33:4210-4218.
39. Moslehi JJ Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33:4210-4218.
40. Kantarjian HM Cortes JE Kim DW et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosin kinase inhibitors. Blood. 2014;123:1309-1318.